HESKA CORPORATION (NASDAQ:HSKA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
The following is a summary of the matters voted on at the meeting
based on the report of the voting results by the independent
inspector of elections. The definitive proxy statement related to
the annual meeting, that was filed by the Company with the
Securities and Exchange Commission under cover of Schedule 14A
(File No. 000-22427) on March 24, 2017, contains a description of
the following proposals considered at the annual meeting, each of
which were approved by the Company’s stockholders at the annual
meeting as set forth below:
|
1.
|
Stockholders elected the following two nominees as Class II
directors to serve three-year terms, as follows: |
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker
Non-Voted
|
|
Other
Non-Voted
|
|
David E. Sveen, Ph.D.
|
|
4,858,281
|
|
133,744
|
|
1,230,023
|
|
|
|
Kevin S. Wilson
|
|
4,908,943
|
|
83,082
|
|
1,230,023
|
|
|
until the 2020 annual meeting of stockholders and until their
respective successors are duly elected and qualified.
|
2.
|
Stockholders approved the proposal to approve an amendment to
the Company’s Restated Certificate of Incorporation, as amended, to increase by 1,000,000 the number of authorized shares of each class of the Company’s common stock, as follows: |
|
For:
|
6,104,101
|
|
|
Against:
|
95,610
|
|
|
Abstain:
|
22,337
|
|
|
Broker Non-Voted:
|
|
|
|
Other Non-Voted:
|
|
|
3.
|
Stockholders ratified the appointment of EKSH LLLP as the
Company’s independent registered public accounting firm for the year ending December 31,2017, as follows: |
|
For:
|
6,181,397
|
|
|
Against:
|
22,720
|
|
|
Abstain:
|
17,931
|
|
|
Broker Non-Voted:
|
|
|
|
Other Non-Voted:
|
|
|
4.
|
Stockholders approved the Company’s executive compensation
in a non-binding advisory vote, as follows: |
|
For:
|
4,886,168
|
|
|
Against:
|
46,083
|
|
|
Abstain:
|
59,774
|
|
|
Broker Non-Voted:
|
1,230,023
|
|
|
Other Non-Voted:
|
|
About HESKA CORPORATION (NASDAQ:HSKA)
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It offers blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. HESKA CORPORATION (NASDAQ:HSKA) Recent Trading Information
HESKA CORPORATION (NASDAQ:HSKA) closed its last trading session down -3.13 at 87.07 with 90,786 shares trading hands.
